<DOC>
	<DOCNO>NCT00367055</DOCNO>
	<brief_summary>It show previous study progressive glycemic deterioration associate progressive loss b-cell function , measure decrease plasma insulin level , irrespective therapy use ( diet , sulfonylureas metformin ) .There grow evidence thiazolidinediones could positive action b-cell function . But yet demonstrate could protect deterioration insulin secretion long term . So , appear interesting study long term evolution b-cell function possible protection rosiglitazone patient type 2 diabetes show evidence loss b-cell function metformin alone .</brief_summary>
	<brief_title>Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Gliclazide</mesh_term>
	<criteria>INCLUSION CRITERIA : Males females 40 75 year age ( inclusive time screen ) Type 2 diabetes mellitus define WHO criterion , diagnose least 1 year Subjects receive 1.5 3g metformin alone constant dose least 8 week prior visit 1 Patients 6.5 % &lt; HbA1c &gt; 8 % visit 1 visit 2 25 &lt; BMI &lt; 35 EXCLUSION CRITERIA : Patient type 1 diabetes Treatment hypoglycaemic agent metformin last 3 month FPG &gt; 200 mg/dL visit 2 Hypersensitivity study treatment ( rosiglitazone , metformin chlorhydrate , gliclazide ) Congestive heart failure ( NYHA class I IV ) , unstable severe angina , recent myocardial infarction Respiratory insufficiency Subjects require use insulin glycaemic control past 6 month prior visit 1 ( except pregnancy acute episodes hospitalization , trauma infection ) subject history metabolic acidosis include diabetic ketoacidosis Anemia define haemoglobin concentration &lt; 11.0 g/dL male &lt; 10.0 g/dL female Renal disease renal dysfunction , e.g . suggest serum creatinine level ≥135.0 µmol/L male ≥110.0 µmol/L female and/or creatinine clearance &lt; 40 mL/min Presence clinically significant hepatic disease , ALT , AST , total bilirubin , alkaline phosphatase &gt; 2.5 time upper limit normal reference range Subjects chronic disease require periodic ot intermittent treatment oral IV corticosteroid Subjects receive danazol , miconazole phenylbutazone Active alcohol , drug medication abuse within last 6 month condition would indicate likelihood poor subject compliance Women lactating , pregnant planning become pregnant Any clinically significant abnormality identify screening , investigator 's judgement , make subject unsuitable inclusion study Use investigational agent within 30 day 5 halflives ( whichever longer ) prior visit 1 Subjects receive anticipate receive radiocontrast dye study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Beta cell function</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Combination treatment</keyword>
</DOC>